AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
In Amarin’s REDUCE-IT clinical trial of 8,179 statin-treated adults with increased risk of cardiovascular problems, the drug showed a 25 percent relative risk reduction in major adverse cardiovascular events compared to placebo.
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.
Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for Atherosclerosis
Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.
Denmark-based Zealand Pharma announced that the company’s Phase III trial for dasiglucagon for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints, setting up potential regulatory approval.
Allergan and the company’s development partner Sosei Group voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.
Viking Therapeutics Inc.’s shares more than doubled in value after promising data from a mid-stage trial of the company’s fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals.
Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial that showed the triple combination therapy PT010 outperformed dual-therapy rivals eight of nine times.
China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.
Almost half of all European-registered clinical trials have breached EU rules by failing to report results, according to a published analysis.
People who have trouble falling asleep and staying asleep may want to seek advice from a doctor and avoid long-term use of sleeping pills, medical experts advise.
Cancer will claim the lives of 9.6 million people in 2018, accounting for one in eight of all deaths among men and one in 11 among women, the WHO’s cancer research agency said.
Vital Therapies Inc. will explore strategic options after the U.S. biotech firm’s liver disease treatment failed to meet the main goal of a late-stage study, driving its shares down more than 70 percent.
Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Galapagos to an all-time high as analysts forecast multibillion-dollar sales.
Bristol-Myers Squibb’s experimental drug BMS-986165 helped reduce the severity of the most common form of psoriasis in a mid-stage trial.
Foamix Pharmaceuticals Ltd.’s lead drug for treating moderate-to-severe acne met the main goals of the company’s third late-stage study, sending its shares up 57 percent in extended trading.
Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).
EpicGenetics and Massachusetts General Hospital are launching a Phase II clinical trial to test a tuberculosis vaccine, CBG, as a potential treatment for fibromyalgia.
Merck KGaA said the immunotherapy Bavencio, jointly developed with Pfizer Inc., delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.